Evaluating the Market Impact of Trump's Medical Marijuana Reclassification

By Patricia Miller

Apr 24, 2026

2 min read

Trump's reclassification of medical marijuana has shifted prediction markets and created new investment opportunities.

#How Has Trump's Reclassification of Medical Marijuana Affected Market Predictions?

Trump's recent decision to reclassify medical marijuana as Schedule III has notably impacted prediction markets. The market probability of marijuana being rescheduled by December 31 decreased to 42.8% from 62% just a day earlier. This change reflects the evolving perspectives surrounding cannabis regulation.

#What is the Market Reaction?

The market has shown a clear split in expectations for short and long-term actions regarding the reclassification. Contracts scheduled for June 30 have seen approval probabilities plummet to just 9.5%, indicating a prevailing skepticism about imminent regulatory changes. While the December 31 contracts also decline, they remain notably higher than their June counterparts, which suggests that traders foresee regulatory delays but still anticipate a likely resolution by year-end.

#Why is This Important?

The trading volume for the December 31 contract stands at $46,442 USDC daily, illustrating the active interest in this market. However, the order book is not deep; only $775 is needed to adjust prices by 5 points. A significant recent market reaction included an 8-point spike followed by a return to previous levels, indicative of reactive trading in a low-liquidity market. Such dynamics highlight that while Trump's directive offers partial market clarity, ongoing uncertainty regarding implementation timelines is suppressing prices. Currently, a YES share priced at 43¢ would yield a 2.33x return if rescheduling occurs by December 31, demonstrating that traders are factoring in considerable risks of delays.

#What Should Investors Keep an Eye On?

The most crucial factor for investors will be the DEA’s subsequent actions. Any announcements regarding Federal Register filings or expedited hearings will play a pivotal role in shaping the timeline for reclassification. Statements from Terrance Cole, the DEA Administrator, alongside movements from the Attorney General's office or Congress, will have significant implications for this evolving situation and the markets tied to it.

Important Notice And Disclaimer

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.